Astellas, SeaGen: Keytruda Combo Improves Survival in Phase 3 for Bladder Cancer

 Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") and Seagen Inc. (Nasdaq: SGEN) today announced positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) for PADCEV^® (enfortumab vedotin-ejfv) in combination with KEYTRUDA^® (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC), a form of bladder cancer that has spread to surrounding organs or muscles, or other parts of the body. The EV-302 trial enrolled patients with previously untreated la/mUC who were eligible for cisplatin- or carboplatin-containing chemotherapy regardless of PD-L1 status.

https://www.biospace.com/article/releases/padcev-enfortumab-vedotin-ejfv-and-keytruda-pembrolizumab-significantly-improve-overall-survival-and-progression-free-survival-in-patients-with-previously-untreated-advanced-bladder-cancer-in-pivotal-phase-3-ev-302-trial/